Abstracts tagged "fibrosis"

Abstract Number: 1707 • 2017 ACR/ARHP Annual Meeting
Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
Viktor Martyanov¹, Yolanda Nesbeth², Guoshuai Cai¹, Tammara A. Wood¹, Jake Reder², Scott Constantine³, Barbara White³, Robert F. Spiera⁴ and Michael L. Whitfield¹, ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Celdara Medical, LLC, Lebanon, NH, ³Corbus Pharmaceuticals, Inc., Norwood, MA, ⁴Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Anabasum (JBT-101) is a non-immunosuppressive, synthetic, CB2 agonist that resolves inflammation and fibrosis in animal models of SSc and reduces TGF-β and collagen production…
Abstract Number: 1708 • 2017 ACR/ARHP Annual Meeting
Molecular Imaging Biomarkers for Personalized Medicine Strategies in Systemic Sclerosis-Related Interstitial Lung Disease
Janine Schniering¹, Martina Benesova^2,3, Matthias Brunner⁴, Carol A. Feghali-Bostwick⁵, Roger Schibli^2,3, Oliver Distler⁶, Cristina Müller^2,3 and Britta Maurer⁶, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ²Department of Chemistry and Applied Biosciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland, Zurich, Switzerland, ³Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen-PSI, Switzerland, Villigen PSI, Switzerland, ⁴Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁵Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC, ⁶Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a life-threatening complication in SSc. In recent years, distinct genomic and molecular subtypes in SSc-ILD were identified and molecular…
Abstract Number: 1718 • 2017 ACR/ARHP Annual Meeting
The Role and Function of Monocyte-Derived Fibroblast-like Cells in Multi-Organ Fibrosis in Systemic Sclerosis
Michal Rudnik¹, Mara Stellato¹, Vincent Milleret², Przemyslaw Blyszczuk^1,3, Britta Maurer¹, Karin Klingel⁴, Joerg C. Henes⁵, Karl Sotlar⁶, Martin Ehrbar², Oliver Distler⁷ and Gabriela Kania¹, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Obstetrics, University Hospital Zurich, Zurich, Switzerland, ³Department of Clinical Immunology, Jagiellonian University Medical College, Krakow, Poland, ⁴Department of Molecular Pathology, University Hospital Tuebingen, Tuebingen, Germany, ⁵Department of Internal Medicine II, Division of Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, ⁶Institute of Pathology, Ludwig Maximilians University, Munich, Germany, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Animal studies indicated bone marrow-derived cells as a source of pathological myofibroblasts in fibrosis of multiple organ including lungs, heart, skin and kidney. Monocytes…
Abstract Number: 1720 • 2017 ACR/ARHP Annual Meeting
TGF-ß-Induced Tissue Fibrosis in TBRIcaCol1Cre Transgenic Mice Is Abrogated By the Second Generation Tyrosine Kinase Inhibitor SKI-606 (Bosutinib)
Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Bosutinib (SKI-606), a second-generation tyrosine kinase inhibitor that blocks the activity of the BCR-ABL kinase responsible for Philadelphia chromosome positive chronic myeloid leukemias, also…
Abstract Number: 1721 • 2017 ACR/ARHP Annual Meeting
Long Noncoding RNA H19X Is a Key Regulator of Apoptosis and Proliferation of Fibroblasts in Systemic Sclerosis and Other TGFβ-Driven Fibrotic Diseases
Elena Pachera¹, Adam Wunderlin¹, Shervin Assassi², Gloria Salazar², Mojca Frank Bertoncelj¹, Rucsandra Dobrota¹, Matthias Brock³, Carol A. Feghali-Bostwick⁴, Gerard Dijkstra⁵, Gerhard Rogler⁶, Tobias van Haaften Wouter⁶, Jörg Distler⁷, Gabriela Kania¹ and Oliver Distler¹, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ³Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland, ⁴Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC, ⁵Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Switzerland, ⁶Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, ⁷Internal Medicine 3, University of Erlangen, Erlangen, Germany
Background/Purpose: Long noncoding RNAs (lncRNAs) are a class of transcripts regulating gene expression. We have recently identified a novel lncRNA, H19X, which was upregulated in…
Abstract Number: 298 • 2017 ACR/ARHP Annual Meeting
Anabasum (JBT-101) Enhances Resolution of Inflammation in Humans
Madhur Motwani¹, Fran Bennett¹, Mark Tepper², Barbara White², Paul Norris³, Raymond MacAllister¹, Charles Serhan³ and Derek Gilroy¹, ¹University College London, London, United Kingdom, ²Corbus Pharmaceuticals, Norwood, MA, ³Harvard Medical School, Cambridge, MA
Background/Purpose: Certain rheumatic diseases including systemic sclerosis (SSc) are characterized by chronic activation of innate immune responses, leading to excessive fibrosis. A normal innate…
Abstract Number: 1725 • 2017 ACR/ARHP Annual Meeting
Insulin-like Growth Factor Binding Protein-4 Exerts Anti-Fibrotic Effects and Its Levels Are Reduced in SSc-Associated Lung Fibrosis
Yunyun Su¹, Stanley Hoffman² and Carol A. Feghali-Bostwick³, ¹Medicine, Division of Rheumatology and Immunology, Medical University of South Carolina, charleston, SC, ²Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ³Division of Rheumatology and Immunology, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, United States, Charleston, SC
Background/Purpose: The Insulin-like growth factor (IGF) system plays an important role in cellular growth, proliferation, differentiation, apoptosis and transformation; IGF binding proteins (IGFBP) exert cell…
Abstract Number: 552 • 2017 ACR/ARHP Annual Meeting
Mast Cells Are Involved in the Pathogenesis of Sjögren Syndrome By Inducing Tissue Fibrosis
Shinjiro Kaieda¹, Kyoko Fujimoto², Masaki Okamoto³, Masaki Tominaga², Tomoaki Hoshino⁴ and Hiroaki Ida⁵, ¹Department of Medicine, *Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, kurume, Japan, ²Kurume University School of Medicine, Kurume, Japan, ³Medicine, Kurume University School of Medicine, Kurume, Japan, ⁴Department of Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, ⁵Respiorogy, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan
Background/Purpose: Mast cells have been implicated in many immune-inflammatory disorders. They mediate a variety of inflammatory and fibrotic conditions, but their role in sialadenitis and…
Abstract Number: 1924 • 2017 ACR/ARHP Annual Meeting
The Nuclear Receptor ROR-Alpha As a Key Checkpoint of Tissue Repair
Rosebeth Kagwiria¹, Ruifang Liang², Chih-Wei Chen³, Thomas Burris⁴, Georg Schett⁵ and Jörg Distler⁶, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of pharmacology and physiology, Saint Luis University-school of medicine, Florida, USA, St. Louis, Missouri, MO, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: The Retinoic-acid related Orphan Receptor-alpha (RORα) is a member of the nuclear receptor superfamily and a ligand-dependent transcription factor implicated in a wide range…
Abstract Number: 1850 • 2016 ACR/ARHP Annual Meeting
Optimization of a Murine Model to Recapitulate Dermal and Pulmonary Features of SSc
Tomoya Watanabe¹, Tetsuya Nishimoto², Jonathan Heywood³, Stanley Hoffman⁴, Logan Mlakar⁴ and Carol A. Feghali-Bostwick⁵, ¹Rheumatology, Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Rheumataology, Medical University of South Carolina, Chareston, SC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: The murine bleomycin (BLM)-induced fibrosis model is the most widely used in systemic sclerosis (SSc) studies. Traditionally, daily subcutaneous injections of BLM for 4-6…
Abstract Number: 1852 • 2016 ACR/ARHP Annual Meeting
Decreased Expression of Sirtuin 7 By Lung Fibroblasts from Patients with Scleroderma Contributes to Elevated Collagen Production
Anne E. Wyman^1,2, Zahid Noor¹, Nevins W. Todd^1,2, Irina G. Luzina^1,2 and Sergei P. Atamas^1,2, ¹University of Maryland School of Medicine, Baltimore, MD, ²Baltimore VA Medical Center, Baltimore, MD
Background/Purpose: Pulmonary fibrosis is a severe complication of systemic sclerosis (SSc). Changes in the expression levels of sirtuins (SIRTs), a family of NAD+-dependent histone deacetylases,…
Abstract Number: 1859 • 2016 ACR/ARHP Annual Meeting
Fucosyltransferase-1 Mediated Fucosylation of TGF-βR1 Is Critical to TGF-β Signaling in Scleroderma and in Bleomycin-Induced Fibrosis
W. Alexander Stinson¹, Pei-Suen Tsou^1,2, Yuxuan Du³, Huadong Cui¹, Ellen Cealey³, Nicholas Lepore⁴, Ray A. Ohara¹, Gautam Edhayan¹, Sarah Arwani¹, Rachel Morgan¹, Dinesh Khanna^1,2, David A. Fox¹ and M. Asif Amin⁵, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²University of Michigan Scleroderma Program, Ann Arbor, MI, ³Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴University of Michigan, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by systemic fibrosis. The dysregulation of transforming growth factor-β (TGF-β) signaling causes proliferation of myofibroblasts…
Abstract Number: 1860 • 2016 ACR/ARHP Annual Meeting
Activating Transcription Factor 3 – a New Linkage Between Vasculopathy and Organ Fibrosis in Systemic Sclerosis
Thomas Wohlfahrt¹, Alina Soare², Tatjana Mallano², Morgane Gourlaouen³, Stephen Moss³, Britta Maurer⁴, Oliver Distler⁴, Tsonwin Hai⁵, Georg Schett², Jörg Distler² and Andreas Ramming², ¹Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Institute of Ophthalmology, Department of Cell Biology, University College London, London, United Kingdom, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Department of Molecular and Cellular Biochemistry, The Ohio State University, Colombus, OH
Background/Purpose: Since vascular manifestations such as Raynaud’s phenomenon and morphological changes on nailfold capillaroscopy often precede the onset of other clinical manifestations of systemic sclerosis…
Abstract Number: 1862 • 2016 ACR/ARHP Annual Meeting
Modelling Healthy and Scleroderma Fibrotic Skin in Vitro: Mechanical Stress Alters Macrophage Cytokine Expression and Triggers Signalling Via the Mechano-Sensing Transcription Factor Myocardin-Related Transcription Factor-a
Angela Tam¹, Shiwen Xu¹, Henry Lopez¹, Korsa Khan², Bahja Ahmed Abdi³, Henrique Rosario⁴, Nikita Arumalla², Mark Gibson², Christopher Denton², David Abraham², Barbara D Smith⁵ and Richard J Stratton², ¹Division of Medicine, Centre for Rheumatology and Connective tissue disease, University College London, London, United Kingdom, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Division of Medicine, Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁵Boston University School of Medicine, Boston, MA
Background/Purpose: Skin involvement is one of the most prominent clinical features in scleroderma. There is a marked contrast in mechanical stiffness between healthy forearm skin…
Abstract Number: 2068 • 2016 ACR/ARHP Annual Meeting
Type 2 Innate Lymphoid Cells – Cellular Source of Profibrotic Mediators Rapidly and Persistently Recruited in Experimental Fibrosis and Systemic Sclerosis
Stefanie Weber¹, Thomas Wohlfahrt¹, Simon Rauber¹, Markus Luber¹, Matthias Englbrecht², Clara Dees³, Christian Beyer⁴, Oliver Distler⁵, Georg Schett³, Joerg HW Distler³ and Andreas Ramming⁴, ¹Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: We aimed to profile ILC2s in fibrotic tissues and to evaluate the functional impact of IC2s in the pathogenesis of systemic sclerosis (SSc). Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.